Skip to main content
LSL Pharma Group Inc. logo

LSL Pharma Group Inc. — Investor Relations & Filings

Ticker · LSL ISIN · CA50190N1042 TSXV Manufacturing
Open in API
Filings indexed 300 across all filing types
Latest filing 2024-05-30 Regulatory Filings
Country CA Canada
Listing TSXV LSL

About LSL Pharma Group Inc.

https://www.groupelslpharma.com/en

LSL Pharma Group Inc. is an integrated pharmaceutical company focused on the development, manufacturing, and commercialization of specialized life sciences products. The company operates multiple manufacturing facilities dedicated to producing a diverse portfolio, including sterile pharmaceutical products, natural health products (NHPs), cosmetic products, food supplements, and vitamins, often in tablet and capsule formats. LSL Pharma Group functions as a Contract Development and Manufacturing Organization (CDMO) for natural and pharmaceutical segments. The company leverages its integrated capabilities to serve domestic and international markets, including strategic distribution agreements aimed at supplying high-quality pharmaceuticals to alleviate drug shortages in hospital environments.

Recent filings

Filing Released Lang Actions
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings
2024-05-30 English
Interim MD&A - English.pdf
Regulatory Filings
2024-05-30 English
Interim financial statements/report – English.pdf
Regulatory Filings
2024-05-30 English
Material change report - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a Material Change Report pursuant to Canadian securities regulation (National Instrument 51-102) describing the listing of Convertible Unsecured Redeemable Debentures on the TSX Venture Exchange. It includes details about the debentures, their maturity, interest rate, conversion rights, and trading symbol. The document is essentially an announcement of a financing event and capital structure update, specifically about the listing and trading of new debentures. It is not a full financial report, audit, or earnings release, nor is it a regulatory certification or voting result. The content fits best under Capital/Financing Update (CAP) as it relates to new capital instruments being listed and traded. The document length (6045 characters) and content confirm it is a substantive announcement, not just a brief notice or report publication announcement. Therefore, the classification is CAP with high confidence.
2024-05-24 English
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a press release announcing the listing of convertible redeemable debentures on the TSX Venture Exchange (TSXV). It details the terms of the debentures, including maturity date, interest rate, and conversion price. The document does not contain financial statements or detailed financial analysis but rather provides an update on a financing activity. It also includes cautionary forward-looking statements typical of such announcements. The document length is 3841 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document fits best under the category of Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities.
2024-05-22 English
Notice of the meeting and record date - French.pdf
Declaration of Voting Results & Voting Rights Announcements Classification · 90% confidence The document is a notification from Compagnie Trust TSX regarding the annual and extraordinary general meeting of Groupe LSL Pharma Inc. It provides details such as the meeting date (June 28, 2024), record dates for notice and voting (May 22, 2024), and information about the categories of shares entitled to notice and voting rights. The document is short (2014 characters) and serves as a formal announcement of the meeting and related record dates rather than the meeting materials or results themselves. It does not contain financial data, management discussion, or voting results. Therefore, it is best classified as a Declaration of Voting Results & Voting Rights Announcements (DVA) type, as it relates to official notices about shareholder meeting dates and voting rights. However, since it is a notice of meeting and record dates rather than actual voting results, it aligns more closely with DVA than AGM-R or PSI. Confidence is high due to clear meeting and record date details and the nature of the document as a formal notice to exchanges and regulators.
2024-05-14 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.